Dexcom Inc

Dexcom Inc

DXCM

Get informed when a big investor buys or sells

+ Follow
Market Cap$32.2B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Dexcom IncDexcom Inc32.2-38%70.5

Earnings Call Q2 2026

July 30, 2026 - AI Summary

Strong top-line execution; guidance raised - Q2’26 worldwide revenue: $1.31B, +13% YoY reported (+12% organic). - U.S. revenue: $933M (+11%); sequential uptick in new patient starts. - International revenue: $375M (+19%); organic +16%, with strength in newly expanding-access markets (e.g., France, Canada). - Full-year revenue guidance raised to $5.18B–$5.25B (~+11% to +13% YoY at midpoint), with FX headwind of about $15M in 2H vs prior outlook.
Profitability improved materially; operating leverage continues - Gross margin: 64.1% (up from 60.1% YoY; ~+400 bps), driven by manufacturing efficiencies/quality management and initial customer switch to G7 15-day plus shipping-pattern optimization. - Non-GAAP operating income margin: 25.1% of revenue; Adjusted EBITDA: $421.3M (32.2% margin). - Guidance raised on margins/EBITDA: - Non-GAAP gross margin: ~64% - Non-GAAP operating profit margin: 23.5%–24% - Adjusted EBITDA margin: 31.5%–32% - Cash generation: ended Q2 with ~$1.9B cash/cash equivalents; delivered > $600M free cash flow in 1H, more than double 1H’25.
Share repurchase actively underway (capital return) - Announced $1B share repurchase authorization for 2026 at Investor Day; executed ~$600M in Q2. - No dividend mentioned in the call excerpt (investor focus was buybacks + reinvestment).

Exclusive for Stockcircle Pro members

Sign upSign Up
$87.09

Target Price by Analysts

4.4% upsideDexcom Target Price DetailsTarget Price
$68.52

Current Fair Value

17.9% downside

Overvalued by 17.9% based on the discounted cash flow analysis.

Share Statistics

Market cap$32.20 Billion
Enterprise Value$32.44 Billion
Dividend Yield$- (-)
Earnings per Share$2.14
Beta1.45
Outstanding Shares383,700,000

Return

Return on Equity38.14%ROE
Return on Assets15.49%
Return on Invested Capital27.70%

Valuation & Multiples

P/E Ratio32.22P/E Ratio
PEG83.6PEG
Price to Sales6.95Price to Sales
Price to Book Ratio13.91Price to Book Ratio
Enterprise Value to Revenue6.53
Enterprise Value to EBIT28.58
Enterprise Value to Net Income32
Total Debt to Enterprise0.04
Debt to Equity0.51Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
July 30, 2026
EPS Estimate
$0.61
Average shareholder expectation
Revenue Estimate
$1.29 B
Average shareholder expectation

Next Earnings Call

Expected Date
October 29, 2026
EPS Estimate
$0.67
Average shareholder expectation
Revenue Estimate
$1.33 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000▼ 90.41%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %4.84%▼ 89.21%
Total Invested$1.25B▼ 94.51%
Investors Holding352▼ 652.00%

ESG Score

No data

About Dexcom Inc

CEO: Kevin Sayer

Relevant Senate Committees

Finance

This committee controls taxation, trade, and entitlement spending, including Medicare and Medicaid. Decisions on Medicare reimbursement rates for medical devices are critical for Dexcom's revenue, and tax policy directly impacts its profitability.

Health, Education, Labor, and Pensions

This committee directly regulates the FDA, which is the primary regulatory body for medical device approval. Decisions regarding product approvals, safety standards, and market access are fundamental to Dexcom's business.

Veterans' Affairs

This committee's funding decisions for the Department of Veterans Affairs directly impact government healthcare contractors and medical device manufacturers like Dexcom, whose products are often used by veterans and covered by VA healthcare.